Developer docs
API playgroundTry for free, no card

Search company profiles

BioProtect

Full company profile

uuid0000vus

Namestring
BioProtect
Legal namestring
BioProtect Ltd.
Websiteurl
bioprotect.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

BioProtect Ltd. is an Israel-based medical device company that develops and commercializes the BioProtect Balloon Spacer (BioProtect Balloon Implant System), a pre-formed, biodegradable balloon implant made of Poly(L-lactide-co-ε-caprolactone) (PLCL) that is placed via the transperineal route under transrectal ultrasound guidance and inflated in situ with saline to create 10–18 mm of uniform prostate–rectum separation during radiation therapy for prostate cancer. The device is fully bioresorbed by the patient over the course of treatment, is visible under TRUS, CT, and MRI, and is the only FDA-cleared (510(k) K222972, August 2023) non-gel balloon spacer in the rectal-protection category, supported by a pivotal Phase III RCT of 222 patients and 26+ peer-reviewed publications. BioProtect's clinical positioning emphasizes consistent base-to-apex spacing, SBRT-grade rectal dose reduction (>84% rV70 reduction), and four-year sustained bowel, urinary, and sexual quality-of-life preservation as differentiated performance versus gel-based hydrogel spacers (SpaceOAR, Barrigel).

The company sells the device as a single-use implantable medical device to urologists, radiation oncologists, physicists, dosimetrists, hospitals, and ambulatory surgical centers, with procedure-based Medicare reimbursement of approximately $5,114 in the HOPD setting and $4,248 in the ASC setting (CPT 55874, HCPCS C1889). The go-to-market is built on direct field sales, a hands-on physician and resident training program, a multi-episode masterclass series, and a deep presence at ASTRO, AUA, ABS, and regional urological society meetings. Since the 2023 US commercial launch, more than 11,000 procedures have been performed worldwide and BioProtect generated approximately $14.5 million in 2025 revenue. In May 2026, Olympus Corporation signed a definitive agreement to acquire BioProtect for $270 million (expected to close end of Q2 2026), making the company part of Olympus's global urology and oncology commercial channel.

Short descriptiontext

BioProtect Ltd. develops and commercializes the BioProtect Balloon Spacer, a biodegradable PLCL balloon implant placed transperineally to create prostate–rectum separation during radiation therapy for prostate cancer. It sells the FDA-cleared device to urologists, radiation oncologists, hospitals, and ASCs, and is now part of Olympus following a $270M acquisition.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNetanya, Israel
HQ citystring
Netanya
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
prostate radiation spacer, biodegradable balloon implant, rectal protection device, radiation oncology devices, prostate cancer treatment
Industry2 codes
PRIMARYHLAKAFAC
Radiation Oncology
SECONDARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code3 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Irradiation Apparatus Manufacturing334517
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • X-Ray Apparatus & Tubes & Related Irradiation Apparatus3844
Product category
Radiation Oncology Medical Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1BioProtect Balloon Implant Device Sales
TypeHardware Sales
Description

Revenue generated from sale of the FDA-cleared BioProtect Balloon Implant System to hospitals, ambulatory surgical centers, and physician offices for use during prostate cancer radiation therapy. Approximately $14.5 million in revenue in 2025; over 11,000 procedures performed since 2023 commercial launch. Device is billed via CPT 55874 with HCPCS C1889 for the biodegradable spacer material.

prnewswire.com
2Procedure Reimbursement-Driven Sales
TypeHardware Sales
Description

Hospital Outpatient Department payment of approximately $5,114 per procedure and ASC payment of approximately $4,248 for CPT 55874 transperineal placement of biodegradable material, supporting the per-unit economics that drive device adoption and recurring hospital purchasing.

bioprotect.com
Marketing channels13 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Operations, Infrastructure
Pricing details3 tiers
1CPT 55874 - Transperineal placement of biodegradable material, periprostatic (Hospital Outpatient / ASC)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Hospital Outpatient Department: $5,114; Ambulatory Surgical Center: $4,248; Physician PRO (HOPD or ASC): $144; Physician Office / Freestanding Facility (Global fees): $3,767. HCPCS C1889 used to report implantable device for device-intensive procedures. 2026 Medicare rates, subject to change.

bioprotect.com
2CPT 55876 - Placement of fiducial marker into prostate for radiation therapy guidance
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Hospital Outpatient Department: Packaged ($1,428 if performed on separate date of service); ASC: $998.68; Physician PRO: $92; Physician Office / Freestanding Facility: $154.

bioprotect.com
3CPT 77387 (formerly G6002) - Image guidance utilizing stereoscopic X-ray guidance
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Not billed in Hospital Outpatient setting; Ambulatory Surgical Center: $37; Physician PRO: $37.

bioprotect.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1BioProtect Balloon Spacer
Description

The company's flagship product brand: a biodegradable balloon implant system that creates spacing between the prostate and rectum during prostate cancer radiation therapy to protect healthy tissues.

bioprotect.com
+1 more record
Core offering1 text field

BioProtect develops, manufactures, and sells the BioProtect Balloon Spacer (BioProtect Balloon Implant™ System), an FDA 510(k)-cleared, biodegradable balloon implant placed via the transperineal route under transrectal ultrasound guidance and inflated with saline to create 10–18 mm of prostate–rectum separation during radiation therapy for prostate cancer. The device is fully bioabsorbed by the patient after treatment and is sold to hospitals, ambulatory surgical centers, and urology/radiation oncology practices, supported by physician training, clinical evidence, and reimbursement services.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

BioProtect offers a single unified core product, the BioProtect Balloon Spacer (BioProtect Balloon Implant™ System), a biodegradable, pre-formed balloon implant placed via a transperineal approach and inflated with saline to create 10–18 mm of prostate–rectum separation during prostate cancer radiation therapy. The core product is delivered alongside an integrated ecosystem of clinical and educational services that support adoption and use, including the BioProtect Balloon Spacer Procedure (workflow and placement guidance), a Physician Training Program, a Resident Training Program, BioProtect Masterclasses (live and on-demand expert education), the BioProtect Resource Center (imaging library and downloadable materials), the BioProtect Clinical Evidence Program (pivotal phase III trial and 20+ supporting studies), and BioProtect Reimbursement Support (Medicare billing codes and payment rates). Together, the device plus these training, evidence, and reimbursement services form a single platform for integrating balloon spacing into prostate cancer radiotherapy practice; BioProtect became part of Olympus in 2026.

Product and service1 record
1BioProtect Balloon Spacer (BioProtect Balloon Implant™ System)
CategoryImplantable medical device — biodegradable balloon spacer
Description

The BioProtect Balloon Spacer is a pre-formed, biodegradable (Poly(L-lactide-co-ε-caprolactone), PLCL) balloon implant placed via a transperineal approach under TRUS guidance and inflated in situ with standard 0.9% saline to create 10–18 mm of uniform prostate–rectum separation during prostate cancer radiation therapy, reducing rectal dose and preserving bowel, urinary, and sexual quality of life; it is fully resorbed by the body after treatment. It is sold to hospitals, ambulatory surgical centers, and urology/radiation oncology practices for use under CPT 55874 with HCPCS C1889.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-26
Description

Olympus Corporation signed a definitive agreement to acquire BioProtect Ltd. for $270 million in May 2026, with completion expected by the end of Q2 2026. The acquisition expands Olympus's urology and oncology portfolio and aligns with its strategic pillar of Innovation-driven Growth; BioProtect becomes part of Olympus's global commercial channel for prostate cancer care technologies.

Strategic tierCoreTypeGTM or Marketing Partner
Description

BioProtect is an industry partner at the American Brachytherapy Society Annual Meeting 2026, hosting booth #110 and a Thursday, June 18, 2026 breakfast symposium titled 'Beyond Placement: Rethinking Rectal Spacing in Modern Brachytherapy' featuring Drs. Chase Hansen, Sagar A. Patel, Albert J. Chang, and Tomer Charas.

Strategic tierCoreTypeGTM or Marketing Partner
Description

BioProtect holds major presence at the American Urological Association Annual Meeting 2026 in Washington D.C. (booth #3815, product theater presentation, VIP educational dinner event titled 'Next-Level Spacing for the Modern Urology Practice', and The Apex Series of in-depth physician presentations).

Strategic tierMinorTypeGTM or Marketing Partner
Description

BioProtect makes sponsored/featured appearances on The Prostate Health Podcast hosted by Dr. Garrett D. Pohlman, with panelists including Dr. Jeffrey Wolters and Dr. Coyt Rountree discussing innovations in prostate cancer care and benefits of BioProtect in urological practice.

Strategic tierMinorTypeGTM or Marketing Partner
Description

BioProtect developed the article 'Spacing for Prostate Radiotherapy: Definitions, Mechanisms, Advancements, and Evolving Strategies' in collaboration with OncoDaily, with original publication on OncoDaily.com.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Owns SpaceOAR, the leading PEG-hydrogel rectal spacer for prostate cancer radiation therapy acquired via Augmenix. Directly comparable as the dominant gel-based competing spacer with overlapping customers (urologists and radiation oncologists) and the same clinical indication.

TypeDirect peer
Description

Markets Barrigel, a hyaluronic acid-based rectal spacer for prostate radiation therapy. Direct competitor in the same clinical indication, cited in BioProtect's own comparative evidence (BioProtect vs. Barrigel in proton therapy).

TypeBroad incumbent
Description

Global leader in radiation oncology hardware and software (linear accelerators, brachytherapy afterloaders, treatment planning). Comparable as the broader ecosystem into which BioProtect's spacer integrates; not a direct spacer competitor but a strategic channel and adjacent incumbent.

TypeBroad incumbent
Description

Radiation oncology systems and software provider (now part of Siemens Healthineers). Comparable as the dominant linear-accelerator and treatment-planning vendor whose installed base defines where BioProtect spacers are used, and a potential integrator of spacer functionality into its planning ecosystem.

TypeBroad incumbent
Description

Provider of brachytherapy seeds and radiation oncology products used in prostate cancer treatment. Comparable as an adjacent incumbent in the prostate radiation therapy workflow that serves the same radiation oncologist customers.

TypeEmerging player
Description

Brachytherapy seed and prostate cancer treatment device company. Comparable as a niche prostate-radiation supplier addressing overlapping radiation oncology buyers, though focused on seeds rather than spacers.

TypeEmerging player
Description

Developer of TULSA-PRO, an MRI-guided transurethral ultrasound ablation system for prostate tissue. Comparable as an emerging, technology-focused prostate cancer therapy company targeting overlapping urology customers seeking tissue-sparing approaches.

TypeEmerging player
Description

Markets Focal One, a robotic HIFU system for prostate tissue ablation. Comparable as a focal-therapy prostate device company selling to the same urologist customer base that places spacers pre-radiation.

TypeEmerging player
Description

Producer of Cesium-131 brachytherapy seeds for prostate cancer. Comparable as a small-cap prostate radiation therapy device vendor addressing the same radiation oncology segment.

TypeOthers
Description

Interventional oncology and vascular device company. Adjacent rather than directly competing — comparable as a mid-sized medtech with overlapping oncology distribution channels and physician relationships.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioProtect

Radiation Oncology Medical Devicesbioprotect.com

BioProtect Ltd. develops and commercializes the BioProtect Balloon Spacer, a biodegradable PLCL balloon implant placed transperineally to create prostate–rectum separation during radiation therapy for prostate cancer. It sells the FDA-cleared device to urologists, radiation oncologists, hospitals, and ASCs, and is now part of Olympus following a $270M acquisition.

What BioProtect does

BioProtect Ltd. is an Israel-based medical device company that develops and commercializes the BioProtect Balloon Spacer (BioProtect Balloon Implant System), a pre-formed, biodegradable balloon implant made of Poly(L-lactide-co-ε-caprolactone) (PLCL) that is placed via the transperineal route under transrectal ultrasound guidance and inflated in situ with saline to create 10–18 mm of uniform prostate–rectum separation during radiation therapy for prostate cancer. The device is fully bioresorbed by the patient over the course of treatment, is visible under TRUS, CT, and MRI, and is the only FDA-cleared (510(k) K222972, August 2023) non-gel balloon spacer in the rectal-protection category, supported by a pivotal Phase III RCT of 222 patients and 26+ peer-reviewed publications. BioProtect's clinical positioning emphasizes consistent base-to-apex spacing, SBRT-grade rectal dose reduction (>84% rV70 reduction), and four-year sustained bowel, urinary, and sexual quality-of-life preservation as differentiated performance versus gel-based hydrogel spacers (SpaceOAR, Barrigel).

The company sells the device as a single-use implantable medical device to urologists, radiation oncologists, physicists, dosimetrists, hospitals, and ambulatory surgical centers, with procedure-based Medicare reimbursement of approximately $5,114 in the HOPD setting and $4,248 in the ASC setting (CPT 55874, HCPCS C1889). The go-to-market is built on direct field sales, a hands-on physician and resident training program, a multi-episode masterclass series, and a deep presence at ASTRO, AUA, ABS, and regional urological society meetings. Since the 2023 US commercial launch, more than 11,000 procedures have been performed worldwide and BioProtect generated approximately $14.5 million in 2025 revenue. In May 2026, Olympus Corporation signed a definitive agreement to acquire BioProtect for $270 million (expected to close end of Q2 2026), making the company part of Olympus's global urology and oncology commercial channel.

BioProtect firmographics

Firmographics
Name
BioProtect
Legal name
BioProtect Ltd.
Website
https://bioprotect.com
Company type
Private
Founded year
2004
Operating status
Acquired
Headcount range
101–250 employees
Short description
BioProtect Ltd. develops and commercializes the BioProtect Balloon Spacer, a biodegradable PLCL balloon implant placed transperineally to create prostate–rectum separation during radiation therapy for prostate cancer. It sells the FDA-cleared device to urologists, radiation oncologists, hospitals, and ASCs, and is now part of Olympus following a $270M acquisition.
Ownership category
akta.pro rank

BioProtect industry classification

Industry
Product category
Radiation Oncology Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391), Irradiation Apparatus Manufacturing (334517), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
akta.pro industry
PRIMARYHLAKAFAC
Radiation Oncology
SECONDARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Prostate radiation spacer
  • Biodegradable balloon implant
  • Rectal protection device
  • Radiation oncology devices
  • Prostate cancer treatment

Where BioProtect is headquartered

Location

Headquarters

HQ city
Netanya
HQ country
Israel
HQ region
Middle East

Markets served

BioProtect business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Operations, Infrastructure

Revenue model

  1. BioProtect Balloon Implant Device Sales: Revenue generated from sale of the FDA-cleared BioProtect Balloon Implant System to hospitals, ambulatory surgical centers, and physician offices for use during prostate cancer radiation therapy. Approximately $14.5 million in revenue in 2025; over 11,000 procedures performed since 2023 commercial launch. Device is billed via CPT 55874 with HCPCS C1889 for the biodegradable spacer material.
  2. Procedure Reimbursement-Driven Sales: Hospital Outpatient Department payment of approximately $5,114 per procedure and ASC payment of approximately $4,248 for CPT 55874 transperineal placement of biodegradable material, supporting the per-unit economics that drive device adoption and recurring hospital purchasing.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCPT 55874 - Transperineal placement of biodegradable material, periprostatic (Hospital Outpatient / ASC)
Unit PricingPay-as-you-goCPT 55876 - Placement of fiducial marker into prostate for radiation therapy guidance
Unit PricingPay-as-you-goCPT 77387 (formerly G6002) - Image guidance utilizing stereoscopic X-ray guidance

Go-to-market motion3 records

Distribution channels2 records

Marketing channels13 records

BioProtect product offering

Product offering

Core offering

BioProtect develops, manufactures, and sells the BioProtect Balloon Spacer (BioProtect Balloon Implant™ System), an FDA 510(k)-cleared, biodegradable balloon implant placed via the transperineal route under transrectal ultrasound guidance and inflated with saline to create 10–18 mm of prostate–rectum separation during radiation therapy for prostate cancer. The device is fully bioabsorbed by the patient after treatment and is sold to hospitals, ambulatory surgical centers, and urology/radiation oncology practices, supported by physician training, clinical evidence, and reimbursement services.

Product overview

BioProtect offers a single unified core product, the BioProtect Balloon Spacer (BioProtect Balloon Implant™ System), a biodegradable, pre-formed balloon implant placed via a transperineal approach and inflated with saline to create 10–18 mm of prostate–rectum separation during prostate cancer radiation therapy. The core product is delivered alongside an integrated ecosystem of clinical and educational services that support adoption and use, including the BioProtect Balloon Spacer Procedure (workflow and placement guidance), a Physician Training Program, a Resident Training Program, BioProtect Masterclasses (live and on-demand expert education), the BioProtect Resource Center (imaging library and downloadable materials), the BioProtect Clinical Evidence Program (pivotal phase III trial and 20+ supporting studies), and BioProtect Reimbursement Support (Medicare billing codes and payment rates). Together, the device plus these training, evidence, and reimbursement services form a single platform for integrating balloon spacing into prostate cancer radiotherapy practice; BioProtect became part of Olympus in 2026.

Differentiator

Problem solved

Functional benefit

Brands

  • BioProtect Balloon Spacer: The company's flagship product brand: a biodegradable balloon implant system that creates spacing between the prostate and rectum during prostate cancer radiation therapy to protect healthy tissues.
  • BioProtect Balloon Implant System

Products and services

  • BioProtect Balloon Spacer (BioProtect Balloon Implant™ System) The BioProtect Balloon Spacer is a pre-formed, biodegradable (Poly(L-lactide-co-ε-caprolactone), PLCL) balloon implant placed via a transperineal approach under TRUS guidance and inflated in situ with standard 0.9% saline to create 10–18 mm of uniform prostate–rectum separation during prostate cancer radiation therapy, reducing rectal dose and preserving bowel, urinary, and sexual quality of life; it is fully resorbed by the body after treatment. It is sold to hospitals, ambulatory surgical centers, and urology/radiation oncology practices for use under CPT 55874 with HCPCS C1889.

Companies that use BioProtect

Customer profile

Named customers11 records

Segments5 records

Ideal customer profiles3 records

BioProtect technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

BioProtect partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship, core and minor.

  • Olympus CorporationflagshipStrategic or Co-development Partner · 26 May 2026Olympus Corporation signed a definitive agreement to acquire BioProtect Ltd. for $270 million in May 2026, with completion expected by the end of Q2 2026. The acquisition expands Olympus's urology and oncology portfolio and aligns with its strategic pillar of Innovation-driven Growth; BioProtect becomes part of Olympus's global commercial channel for prostate cancer care technologies.
  • American Brachytherapy Society (ABS)coreGTM or Marketing PartnerBioProtect is an industry partner at the American Brachytherapy Society Annual Meeting 2026, hosting booth #110 and a Thursday, June 18, 2026 breakfast symposium titled 'Beyond Placement: Rethinking Rectal Spacing in Modern Brachytherapy' featuring Drs. Chase Hansen, Sagar A. Patel, Albert J. Chang, and Tomer Charas.
  • American Urological Association (AUA)coreGTM or Marketing PartnerBioProtect holds major presence at the American Urological Association Annual Meeting 2026 in Washington D.C. (booth #3815, product theater presentation, VIP educational dinner event titled 'Next-Level Spacing for the Modern Urology Practice', and The Apex Series of in-depth physician presentations).
  • Prostate Health PodcastminorGTM or Marketing PartnerBioProtect makes sponsored/featured appearances on The Prostate Health Podcast hosted by Dr. Garrett D. Pohlman, with panelists including Dr. Jeffrey Wolters and Dr. Coyt Rountree discussing innovations in prostate cancer care and benefits of BioProtect in urological practice.
  • OncoDailyminorGTM or Marketing PartnerBioProtect developed the article 'Spacing for Prostate Radiotherapy: Definitions, Mechanisms, Advancements, and Evolving Strategies' in collaboration with OncoDaily, with original publication on OncoDaily.com.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

BioProtect competitors and assessment

Company assessment

Direct peers

  • Boston Scientific: Owns SpaceOAR, the leading PEG-hydrogel rectal spacer for prostate cancer radiation therapy acquired via Augmenix. Directly comparable as the dominant gel-based competing spacer with overlapping customers (urologists and radiation oncologists) and the same clinical indication.
  • Palette Life Sciences: Markets Barrigel, a hyaluronic acid-based rectal spacer for prostate radiation therapy. Direct competitor in the same clinical indication, cited in BioProtect's own comparative evidence (BioProtect vs. Barrigel in proton therapy).

Broad incumbents

  • Elekta: Global leader in radiation oncology hardware and software (linear accelerators, brachytherapy afterloaders, treatment planning). Comparable as the broader ecosystem into which BioProtect's spacer integrates; not a direct spacer competitor but a strategic channel and adjacent incumbent.
  • Varian Medical Systems (Siemens Healthineers): Radiation oncology systems and software provider (now part of Siemens Healthineers). Comparable as the dominant linear-accelerator and treatment-planning vendor whose installed base defines where BioProtect spacers are used, and a potential integrator of spacer functionality into its planning ecosystem.
  • Eckert & Ziegler: Provider of brachytherapy seeds and radiation oncology products used in prostate cancer treatment. Comparable as an adjacent incumbent in the prostate radiation therapy workflow that serves the same radiation oncologist customers.

Emerging players

  • Theragenics: Brachytherapy seed and prostate cancer treatment device company. Comparable as a niche prostate-radiation supplier addressing overlapping radiation oncology buyers, though focused on seeds rather than spacers.
  • Profound Medical: Developer of TULSA-PRO, an MRI-guided transurethral ultrasound ablation system for prostate tissue. Comparable as an emerging, technology-focused prostate cancer therapy company targeting overlapping urology customers seeking tissue-sparing approaches.
  • EDAP TMS: Markets Focal One, a robotic HIFU system for prostate tissue ablation. Comparable as a focal-therapy prostate device company selling to the same urologist customer base that places spacers pre-radiation.
  • IsoRay Medical: Producer of Cesium-131 brachytherapy seeds for prostate cancer. Comparable as a small-cap prostate radiation therapy device vendor addressing the same radiation oncology segment.

Others

  • AngioDynamics: Interventional oncology and vascular device company. Adjacent rather than directly competing — comparable as a mid-sized medtech with overlapping oncology distribution channels and physician relationships.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

BioProtect social profiles

Digital presence

BioProtect compliance and trust

Trust signal

Compliance3 records

BioProtect financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioProtect leadership team

Management profile

Number of profiles

Profiles10 records

BioProtect funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioProtect M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioProtect

What does BioProtect do?

BioProtect develops, manufactures, and sells the BioProtect Balloon Spacer (BioProtect Balloon Implant™ System), an FDA 510(k)-cleared, biodegradable balloon implant placed via the transperineal route under transrectal ultrasound guidance and inflated with saline to create 10–18 mm of prostate–rectum separation during radiation therapy for prostate cancer. The device is fully bioabsorbed by the patient after treatment and is sold to hospitals, ambulatory surgical centers, and urology/radiation oncology practices, supported by physician training, clinical evidence, and reimbursement services.

Is BioProtect a public or private company?

BioProtect is a private company. It is classified as corporate owned and is currently acquired.

When was BioProtect founded?

BioProtect was founded in 2004. It employs 101 to 250 people.

Where is BioProtect based?

BioProtect is headquartered in Netanya, Israel, in the Middle East region.

How does BioProtect make money?

Two revenue lines are on record. BioProtect Balloon Implant Device Sales are the primary driver. The others are procedure Reimbursement-Driven Sales.

Who are BioProtect's main competitors?

Direct peers on record are Boston Scientific and Palette Life Sciences. Broad incumbents are Elekta, Varian Medical Systems (Siemens Healthineers) and Eckert & Ziegler. Emerging players are Theragenics, Profound Medical, EDAP TMS and IsoRay Medical. AngioDynamics is listed as an others.

Does BioProtect have an API?

No public API is recorded for BioProtect.

What industry is BioProtect in?

BioProtect's product category is Radiation Oncology Medical Devices. Its primary akta.pro industry code is HLAKAFAC, Radiation Oncology, with a secondary code of HLAHAEAJ, 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Olympus: $270 Million BioProtect Acquisition Expands Urology And Prostate Cancer PortfolioOlympus signed a definitive agreement to acquire BioProtect for $270 million as part of its strategy to expand into oncology and urology technologies focused on prostate cancer care. BioProtect's Balloon Spacer system, which has been used in over 11,000 procedures since its 2023 commercial launch, creates spacing during radiation therapy to protect healthy tissue and generated approximately $14.5 million in revenue in 2025. The transaction, expected to close by the end of Q2 2026, supports Olympus's growth strategy targeting the anticipated significant expansion of the global rectal spacer market.PR NewswireOlympus to Acquire BioProtect to Expand Its Portfolio of Urological Technologies and Address Prostate CancerOlympus Corporation announced the signing of a definitive agreement to acquire BioProtect Ltd. for $270 million, with completion expected by the end of Q2 2026 subject to customary closing conditions. BioProtect develops the Balloon Spacer system, a biodegradable implant that protects healthy tissues during prostate cancer radiation therapy, which has been used in over 11,000 procedures since its 2023 commercial launch and generated approximately $14.5 million in revenue in 2025 with 130 employees. The acquisition aligns with Olympus's strategic pillar of Innovation-driven Growth, expanding its portfolio in urology and oncology as prostate cancer remains the second most diagnosed cancer among men worldwide with approximately 1.5 million annual diagnoses.Medical Device NetworkOlympus agrees $270m BioProtect buyout to expand prostate cancer offeringsOlympus agreed to acquire BioProtect in a $270m deal to expand its prostate cancer care offerings. BioProtect's Balloon Spacer has been used in over 11,000 procedures since 2023. The acquisition aligns with Olympus's innovation-driven growth strategy.GlobesJapan’s Olympus buys Israeli co BioProtect for $270mOlympus Corporation agreed to acquire Israeli medical device maker BioProtect for $270 million. BioProtect's balloon protects healthy tissue during prostate cancer radiation, with sales rising to $14.5 million in 2025. The company has 130 employees and plans to keep production in Netanya.Mpo-magOlympus to Buy BioProtect for $270 MillionOlympus agreed to acquire BioProtect for $270 million, expanding its oncology and urology businesses. BioProtect's Balloon Spacer, used in over 11,000 procedures, is expected to be completed by Q2 2026. The deal targets prostate cancer care, with the global rectal spacer market projected to grow.FierceBiotechOlympus pushes deeper into oncology with $270M BioProtect dealOlympus agreed to acquire BioProtect for $270 million, adding biodegradable balloon spacer technology for prostate cancer radiation therapy. The FDA-cleared device has been used in over 11,000 procedures, and the deal is expected to close by the end of Q2 2026.CTechOlympus to buy Israel’s BioProtect for $270 million in cashOlympus is acquiring Israeli medtech company BioProtect for $270 million in cash. BioProtect's biodegradable balloon protects healthy tissue during prostate cancer radiation therapy, with over 11,000 procedures performed. The deal is all-cash and expected to accelerate sales via Olympus's global network.MassDeviceOlympus to acquire urologic balloon spacer maker BioProtect for $270MOlympus agreed to acquire urologic device maker BioProtect for $270 million, with escrow held for uninterrupted operations. The deal targets BioProtect's Balloon Spacer, which has performed over 11,000 procedures since 2023. Olympus expects to close by the end of Q2 2026.PR NewswireLong-Term Study Reports Sustained Quality of Life Benefits with the BioProtect Balloon Spacer in Prostate Cancer Radiation TherapyBioProtect announced four-year follow-up data from its pivotal 164-patient randomized trial showing sustained preservation of bowel, urinary, and sexual quality of life outcomes with the BioProtect Balloon Spacer in prostate cancer radiation therapy. The study confirmed this is the only rectal spacing technology to demonstrate statistically significant improvement in patient-reported sexual function through 48 months of follow-up. The device, which received FDA clearance in 2023, is now being used in thousands of patients across the United States and Europe.